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ABSTRACT 
 
 
There is currently no protective vaccine against HIV. It is known that a high 
mutation rate and the existence of many subspecies or clades generated by point 
mutations or recombination events, are at least partly responsible for the ability of the 
virus to escape immune responses elicited by classical vaccines. Protein subunit vaccines 
may not be effective due to this pronounced viral mutability. An immune evasion 
mechanism has been postulated in which variable domains occlude conserved epitopes 
crucial for infectivity. The use of DNA vaccines appeared as a favorable approach.  
 
Here, a DNA vaccine approach is presented in which the DNA constructs have 
been engineered to circumvent the aforementioned problems by 1) introducing elements 
to enhance expression, such as a heterologous promoter, a heterologous signal sequence 
and intron sequences, 2) by optimizing codon usage, and 3) by vaccinating with antigens 
that have a modified glycosylation pattern which will make them more immunogenic. 
The results indicated that deglycosylation of different clades of gp120 did not affect the 
protein conformation, and ‘in vitro’ expression levels were good. Antigen codon 
optimization dramatically increased antibody production. In the animals vaccinated with 
non-codon-optimized constructs, the presence of an intron and a heterologous signal 
sequence was required to achieve a good antibody response. Therefore, antigen 
engineering is required to obtain a powerful immune response against HIV-1 gp120. 
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BACKGROUND 
DNA Vaccines 
 
DNA vaccines consist of transient transfection of naked DNA into target cells. 
The main advantage lies on the fact that the proteins are expressed by the host’s cells. 
Unlike subunit protein vaccines, DNA vaccines are an effective means to elicit cell 
immunity, since the antigens are produced inside the host’s cells and are therefore 
presented via the MHC-I pathway. The secreted proteins can also reach professional 
antigen presenting cells (APCs) triggering MHC-II presentation.  
 
It has been shown that exogenous proteins can also be presented via MHC-I in 
APCs to some extent (Watts, 1997), although these cells usually uptake antigen protein 
from the extracellular space, and present peptides via MHC-II. It is believed that both 
MHC-I and MHC-II presentation pathways are required for an effective immune 
response in which both specific antibody and cytotoxic T lymphocyte (CTL) responses 
are raised (Iwasaki et al., 1997). 
 
In DNA vaccination via the skin, dendritic cells are the major APC type involved 
in presentation (Cella et al., 1997). A particular kind of dendritic cell, the Langerhans’ 
cell, is abundant right underneath the epidermal layer. They are able to uptake the antigen 
and migrate to the lymphoid organs for presentation. The antigen can be processed into 
peptides and presented both via MCH class I and class II. Once in the lymphoid organs, 
Langerhans’ APC’s mature and are able to deliver co-stimulatory signals crucial for T-
cytotoxic and T-helper cell activation.  
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Very little amounts of DNA (micrograms) are sufficient for an immune response 
to be developed. The dose varies with the inoculation method. DNA can be administered 
as ‘naked DNA’ or as liposomes. The most commonly used methods of inoculation are 
intradermal injection (i.d.), intramuscular injection (i.m.) and ‘gene gun delivery’ or 
particle bombardment. The one used in our experiments is the gene gun, and it was very 
efficient in small animal studies (Fynan et al., 1993).  In this technique, DNA is co-
precipitated with calcium chloride onto the surface of microscopic gold beads, which are 
later evenly deposited into the walls lining Teflon tubing. High-pressure propels the 
DNA-coated gold beads into the animal’s skin.  
 
Many other tissues besides skin have been tested as targets for DNA vaccination. 
The ideal tissue target should be easy to access and transfect. In our case, the skin was 
chosen since it can be readily accessed and has been successfully used as a target tissue in 
many other similar DNA vaccination experiments. Gene gun inoculation requires lower 
DNA doses than i.m. and i.d. injections, although i.m. injection requires a single dose in 
mice as opposed to the three doses required for gene gun inoculation (Bohm et al., 1996; 
Hartikka et al., 1996). Nevertheless, intramuscular injection is a variable technique, 
depending on the operator’s skills, whereas the results obtained with the gene gun are 
repeatable and consistent. The transfection efficiency is higher when using the gene gun, 
since the DNA forces its entrance into the cells. The i.m. dose required in mice to raise a 
good immune response ranges from 50 to 100 mg, while with the gene gun, three doses of 
6 mg each are sufficient.  
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Recently, an apparatus called ‘BiojectorTM’ has appeared for intramuscular 
injections. It consists of a needleless syringe driven by CO2 pressure. Its usage results in a 
more even diffusion of the DNA into the muscle tissue. Liposomes improve transfection 
efficiency as compared to naked DNA injection, and they can entrap plasmids, to 
facilitate an efficient ‘in vivo’ transfection method (Gregoriadis et al., 1996). 
Nevertheless, liposome usage is limited to injection procedures so it was not used in the 
present thesis. 
 
DNA is easy to manipulate, raising the possibility of generating designer 
immunogens. Modifications from the original sequence are easy to produce at the DNA 
level. Untranslated sequences can be introduced to enhance expression. Other genetic 
elements can be introduced to modify the subcellular location of the encoded protein. 
Many reports show the utilization of immunostimulatory molecules to enhance or drive 
the immune response to a particular type (Xiang and Ertl, 1995; Kim et al., 1997; Chow 
et al., 1997). For allergy vaccines, it is crucial to bias the immune response towards a Th1 
response, and that has been done by encoding the appropriate cytokines (IL-12, IL-18, 
IFN-g and IFN-a) or chemokines in DNA vaccines (Hsu et al., 1996). The presence of 
immunostimulatory sequences (ISS) in bacterial plasmid DNA was demonstrated long 
ago (Tokunaga et al., 1984). These consist of CpG motifs arranged into palindromic 
sequences (Krieg et al., 1995). ISS have been shown to induce an innate Th1 response by 
macrophage and B-cell activation, and by inducing type I IFN secretion. For some 
intracellular pathogens, such as Listeria monocytogenes or Leishmania major, CpG 
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motifs in DNA vaccines have been used to bias the immune response towards a Th1 
response, which is much more favorable for the immune system to clear the infection 
(Zimmermann et al., 1998; Krieg et al., 1999). 
 
It is possible to encode adjuvants in the DNA constructs either in cis or in trans. It 
has been proven that incorporation of genes encoding cytokines can be useful to bias the 
immune response towards an appropriate branch (i.e. TH1 or TH2) (Lowry and Whalen, 
1999). This is especially important for vaccines against int racellular bacterial or 
protozoan parasites, since a TH2 response would be even more detrimental to the course 
of an infection. Also, protein boosting can enhance the immune response after DNA 
vaccination, either with recombinant protein or using pseudotyped vaccinia virus. 
 
Finally, another advantage of DNA vaccination is their safety. Vaccines based on 
retroviral vectors always have the possibility of pathogenesis or integration in the target 
cell’s genome with the subsequent risk of carcinogenesis. Adenoviral vectors are less 
likely to produce pathogenesis, and they are not integrative, but there is usually a strong 
host immune response against the vector itself, hindering the effectiveness of subsequent 
doses. With DNA vaccines, the DNA is transfected transiently, thus the probability of 
non- integrative DNA molecules entering a cell, integrating randomly in the cell’s 
genome, and activating an oncogene or inactivating a tumor suppressor, is extremely low. 
Some worries were raised relevant to the possibility of anti-DNA antibody induction and 
subsequent generation of systemic lupus erythematosus (SLE) (Gilkenson et al., 1995). In 
that study (Gilkenson et al., 1995) mice were used as a model, and dsDNA was 
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administered along with the Complete Freund’s Adjuvant plus methylated bovine serum 
albumin. It is believed that these accompanying substances were determinant in raising 
anti-DNA antibodies. Anti-dsDNA antibodies could only be induced in mice genetically 
prone to autoimmune disease. Thus, this concern is not completely ruled out, but can be 
reasonably dismissed. 
 
Codon Optimization 
 
When trying to synthesize HIV proteins in mammalian systems, low levels of 
expression were observed (Haas et al., 1996). This is believed to be due to an extreme 
codon bias in HIV genome. The HIV viral RNA is AU-rich, as opposed to the high GC 
content of the mammalian genome. The tRNAs required for viral mRNA translation are 
scarce in mammalian cells, and as a result of this, the viral protein levels are low (Kypr 
and Mrazek, 1987; Stephens et al., 1999). Another factor that contributes to lowering 
HIV expression levels is the existence of instability sequences in the viral mRNA that 
require the Rev regulatory gene product for mRNA stabilization and transport to the 
cytoplasm (Maldarelli et al., 1991; Brighty et al., 1994; Kotsopoulou et al., 2000). This is 
the main disadvantage found for DNA vaccination against HIV. Here we propose codon 
optimization or ‘humanization’ as a means to circumvent this problem. Codon 
optimization will not only be more favorable on terms of tRNA availability, but since it 
involves many modifications in the nucleotide sequence, it will destroy the instability 
sequences. 
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In the present work, a model to prove the efficacy of codon optimization in the 
context of DNA vaccination is presented. If the results are positive, codon optimization 
will be applied to all subsequent gp120 and deglycosylated gp120 constructs. 
 
CMV IE promoter and Intron A 
 
 The Cytomegalovirus Immediate Early (CMV IE) gene promoter and Intron A 
have been shown to enhance expression levels of reporter genes encoded in vectors when 
tested in parallel with other promoters ‘in vitro’ (Pasleau et al., 1985; Chapman et al., 
1991) and ‘in vivo’ (Hartikka et al., 1996; Xu et al., 2001). In this thesis all three vectors 
carry the CMV IE promoter, since its potency is widely accepted. Intron A has been 
shown to cooperate with the CMV IE promoter, yielding even higher expression levels 
(Mikkelsen et al., 1992). Also, a transcription factor binding-sequence is located in the 
Intron A sequence, that is thought to provide a promoter-specific regulatory element 
which might contribute to the enhancing effect of Intron A (Chapman et al., 1991). There 
is direct evidence that splicing and mRNA nuclear export is coupled in higher eukaryotes 
(Luo et al., 1999). According to this and previous studies (Huang and Gorman, 1990), the 
presence of an intron in a pre-mRNA increases the rate of transport into the cytoplasm. 
Early retroviruses, such as simian virus type D, require a cellular factor to bind an 
element in the RNA sequence to trigger efficient mRNA transport (Gruter et al., 1998). 
In the case of HIV, the product of the viral gene Rev, which binds the Rev response 
element sequence (RRE) in the viral mRNA mediating its transport, provides this 
function. Thus, the deletion of the RRE would require the introduction of other elements 
to make up for Rev functions; an intron might be a successful candidate. According to 
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Chapman et al., 1991, the CMV IE Intron A has transcription factor binding sites, which 
was corroborated by Mikkelsen et al., 1992. This fact, as well as spliceability, may 
account for a better expression of constructs containing intron A. Here, the role of intron 
A is tested from an immunological point of view using the immune response generated 
against the encoded antigen as a reporter of this element’s importance. 
 
Tissue Plasminogen Activator Leader Sequence 
 
The HIV-1 env signal sequence has been recently proven to delay its own 
cleavage, therefore slowing down the rate of gp120 folding inside the endoplasmic 
reticulum (Li et al., 2000). Before this direct evidence was provided, substitution 
experiments were conducted in which the HIV leader sequence was removed and other 
glycoprotein leaders were inserted in lieu (Chapman et al., 1991). A very marked 
increase in gp120 production was detected following substitution of HIV-1 env leader 
sequence with tPA leader sequence. In the present report, this effect is reflected in a 
higher specific-antibody production. 
 
N-linked Glycosylation of HIV-1 gp120 
 
The HIV-1 surface protein (gp120) is a glycoprotein. It is initially synthesized in 
the endoplasmic reticulum as a precursor called gp160. gp160 will yield after being 
processed two proteins: the surface protein, gp120, and the transmembrane protein, gp41. 
In some cases, an intermediate size protein – gp140 – is generated in HIV studies. gp140 
contains the full gp120 (surface protein) plus the extracellular domain of gp41 
 8
(transmembrane protein). The immature gp160 protein undergoes folding and addition of 
complex oligosaccharides. One kind of such glycans is the N-linked oligosaccharide. 
Figure 1 shows a scheme of the disposition of the loops in HIV gp140, and the 
glycosylation sites. The functions associated with protein glycosylation are diverse, 
ranging from stabilization of folding intermediates, to cell-to-cell signaling. There is 
evidence supporting the idea that glycosylation of gp120 might actually have a role in 
evading the action of the immune system (Fenouillet et al., 1990; Doe et al., 1994; 
Willey et al., 1996; Chackerian et al., 1997; Edinger et al., 1997; Reitter et al., 1998; 
Mori et al., 2001). Other observations led to the conclusion that the first variable loop in 
gp120 (V1) might be especially involved in immune system evasion (Lee et al., 1992; 
Thali et al., 1993; Wyatt et al., 1995, 1998; Trkola et al., 1996; Wu et al., 1996; 
Dumonceaux et al., 1998; Rizzuto et al., 1998, 2000; Kolchinsky et al., 2001). V1 is a 
highly variable loop among different subspecies, and glycosylation sites on its tip are 
invariably present at different positions. The position of V1 changes upon interaction 
with the primary receptor (CD4), revealing the secondary receptor interaction site. For 
this reason, it is believed that glycosylation on V1 may account for an immune system 
evasion mechanism by which the conserved epitopes are occluded by a highly variable 
(i.e. neutralizing antibody resistant), highly glycosylated loop. Glycosylation on this loop 
might pose a physical obstacle for the antibodies to interact with the conserved epitopes 
underneath. Removal of the glycans on the V1 tip might make the conserved region 
covered by it more accessible to antibodies. In this thesis, in an attempt to reveal putative 
conserved epitopes occluded by N-linked glycans on gp120, several point mutations were 
introduced in the V1 region of gp120 from different HIV-1 subtypes.  
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Figure 1: schematic representation of HIV-1 isolate JR-FL gp140. Note the positions of 
the N-linked oligosaccharides in the V1 and V2 regions. From Binley et al., 2000. 
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Glycoproteins and Immune System Evasion 
Based on several previous studies detailed below, we suspected that env protein 
with glycan residues removed at particular locations might expose conserved antigenic 
determinants without affecting the native conformation of the protein. This raised the 
possibility of removing those carbohydrate residues to elicit neutralizing antibody 
responses.  
 
Generation of CTL responses was enhanced by deglycosylation (Doe et al., 
1994). In that study, gp120 was produced as fully glycosylated native protein, as a 
deglycosylated form, in a denatured form, and in a combination of both denatured and 
deglycosylated. The induction of CTL responses was more efficient when 
deglycosylation prior to denaturing was performed.  
 
Some of the glycosylation sites in gp120 have been proven critical for infectivity. 
In the cell line-adapted HXB2 strain, 5 glycan residues were indispensable for viral 
replication; the remaining 19 could be removed without observing replication 
impediment (Lee et al., 1992). The position of the oligosaccharide residues in several cell 
line adapted-env proteins were compared and it was observed that the relative positions 
were highly conserved in at least half of the sites. Single mutants were constructed, in 
which the Asn in a single canonical glycosylation site was substituted by Gln or His. 
Each mutant was tested for infectivity by syncytium formation and RT activity assays. 
Six mutants showed impaired infectivity as compared to the wild type virus. Mutations 
were also introduced at the same potential glycosylation sites, but in the third canonical 
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residue (Ser/Thr) rather than in the Asn. An infectivity recovery, would have been a sign 
that the loss of infectivity was due to the change of the Asn rather than to the lack of the 
glycan at that particular site. Reversion in the third site mutants was only observed in one 
of the six replication- impaired mutants, leaving five glycosylation sites crucial for HXB2 
HIV replication (Lee et al., 1992). Four of these are located in the hypervariable regions. 
This proved that many glycan residues are involved in functions other than infectivity; 
opening the possibility that glycosylation in gp120 has a role in immune evasion. 
 
An association between viral envelope glycosylation and neutralizing antibody 
activity has been suggested (Willey et al., 1996). In that report, the viral proteins were 
analyzed by radiolabelling virus- infected cells. Two types of cells were tested: peripheral 
blood mononuclear cells (PBMCs) and monocyte derived macrophages (MDMs). After 
SDS PAGE, two distinct patterns were observed in the resolution of the gp120 bands. 
The MDM-derived virus generated a diffuse band whereas the virus-infected PBMC-
derived gp120 had a sharp appearance. This was postulated to reflect a difference in the 
envelope processing mechanisms in these two cell types. An analysis after endoglycanase 
treatment revealed a sharp appearance for the gp120 band derived from both infected cell 
types. Neutralization assays measuring RT activity after infection of PBMC target cells 
with the progeny of MDM or PBMC-infected cells, showed an eight to ten-fold 
difference. The MDM-derived virus was more resistant to neutralization, suggesting that 
the difference in the glycosylation pattern might account for this fact. 
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An experiment in Rhesus macaques revealed the possible importance of the 
glycan moieties in immune evasion (Reitter et al., 1998). Several mutant viruses were 
constructed in which point mutations were introduced to change the canonical N-linked 
glycosylation sequences (Asn to Gln) in the V1 loop. Viral loads in the monkeys infected 
with these mutant SIVs were dramatically reduced until the 12th week post- inoculation, in 
some of them up to the 56th week. The sera were analyzed for ELISA reactivity against 
V1 peptides. Titers were extremely high compared to those obtained with sera from 
monkeys inoculated with the parental virus. The effect occurred both against 
deglycosylated and wild type V1 peptides. Neutralization activity at serum dilution 
higher than 1:1000 was observed against the parental SIV with some antisera collected 
from the deglycosylated mutants. More interestingly, the analysis of the viral progeny 
revealed restoration of the glycosylation, not in the exact same sites, but in their vicinity. 
The percentage variation of the progeny’s genome sequence from the sequence of the 
virus inoculated showed a significant increase as compared to the wild type- infected 
monkeys. This clearly reflects an adaptation of the virus to the immune selective pressure 
exerted by the neutralizing antibodies raised against the conserved domains exposed after 
deglycosylation. In this case, the antibody production was measured against a V1 peptide, 
instead of the whole wild-type gp120. Neutralization was also achieved, but it is not 
known whether the neutralizing antibodies were raised against epitopes in V1 itself or 
against the conserved core domain mentioned in the structural studies described above. 
For this reason, it would be interesting to test cross-neutralization, i.e. to check whether 
neutralization occurs also against divergent isolates, that would support the hypothesis of 
a conserved epitope being exposed by deglycosylation. 
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Some residues in V1 are candidates for deglycosylation, since this loop has been 
known to occlude conserved regions critical for viral entrance. It has been postulated that 
the first two variable loops on HIV-1 gp120 are covering a core structure on gp120 
(Wyatt et al., 1995; Trkola et al., 1996; Wu et al., 1996), that would be exposed upon 
gp120 interaction with CD4. This hypothesis has been further confirmed by X-ray 
crystallography analysis of gp120-soluble CD4 complexes (Wyatt et al., 1998). It was 
also noted that those newly exposed protein domains are conserved epitopes that can be 
recognized by monoclonal antibodies (Thali et al., 1993; Cao et al., 1996; Wyatt et al., 
1998). The ability of gp120 – through its V3 loop – to interact with the co-receptor 
(CCR5 or CXCR4) is influenced by a conserved domain located in the core structure of 
gp120 (Rizzuto et al., 1998, 2000). Some HIV-2 (Endres et al., 1994) and SIV (Edinger 
et al., 1997) isolates are known to be able to infect target cells independently from CD4. 
The same CD4-independent infections have been achieved with HIV-1, after in vitro 
passage in CD4-negative cells (Dumonceaux et al., 1998). All this taken together leads to 
the suggestion that the requirement of CD4 binding to gp120 and further exposure of the 
conserved core domain that interacts with the co-receptor may actually be a mechanism 
of immune evasion, where the outer surface of gp120 is highly variable, but only upon 
interaction with CD4, is a conserved domain crucial for viral fusion with the cell 
revealed. Attempts have been made to expose these conserved epitopes. In one of them 
(Lu et al., 1998), the increase in HIV-1 env immunogenicity was tested after deletions in 
the V1/2 and V3 regions were introduced. The three forms of env (gp160, gp140 and 
gp120) were subject to this deletion. Dr. Lu and co-workers used the DNA vaccine 
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approach to construct mutant plasmids with these deletions, then test for ELISA and 
neutralization antibody production in rabbits. The constructs carrying the deletions 
showed an increase in the immunogenicity for gp140 while the immunogenicity was 
decreased for the gp120 V1/2V3-deleted constructs. Apparently, the deletion caused the 
creation of new epitopes as well as the loss of others. The neutralization was not 
improved in any case, which might suggest that the deletions in V1/2V3 caused a 
significant rearrangement of the protein, and the newly exposed epitopes were different 
from the ones discussed above. In another study (Kolchinsky et al., 2001), an attempt was 
made to expose the conserved epitopes in the gp120 core. This time another kind of 
mutation was introduced: based on previous findings of the possible role of glycans in 
occlusion of conserved epitopes, mutated constructs were analyzed in which the 
canonical N-linked glycosylation sequence was mutated at different positions in V1/V2. 
The results indicate that some of the mutated viruses were CD4-independent for 
infection. Data for co-receptor binding as well as for an infectivity assay were provided, 
as well as a structural model in which an Asparagine- linked oligosaccharide in V1/V2 
appears blocking the gp120-CCR5 interaction site.  
 
Very recently a mutant strain of SIVmac239, with five glycan residues removed 
at the V1/V2 region, has been reported to induce almost complete protection from wild 
type SIVmac239, without any reversions to the glycosylated phenotype being observed 
(Mori et al., 2001). Infection with the mutant resulted in the same viral replication pattern 
as with the wild-type, peaking at 4 weeks after infection, but the chronic pattern typical 
of SIV (and HIV) infection was not observed for the mutant- infected monkeys. 
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Furthermore, these monkeys were able to withstand a challenge with the wild-type virus, 
which resulted in a low replication levels and low chronic infection instead of the typical 
chronic infection pattern. In different stages the researchers were able to amplify proviral 
DNA, and the five deglycosylation mutations remained the same. Surprisingly, analysis 
of the neutralizing activity of the monkey sera revealed low neutralization titers. In other 
studies a low neutralizing antibody response was always observed, usually accompanied 
by high CTL responses (Johnson and Desroisiers, 1998). The authors raised the 
possibility that glycosylation in gp120 might have a role in protection from proteolysis 
prior to antigen presentation. This should be reflected in the CTL assays, but when the 
CTL responses were tested, in most cases they were very similar both in mutant- infected 
monkeys and in wild type- infected. Nevertheless, the CTL responses appeared earlier 
after challenge in the mutant infected monkeys than in the naïve ones, suggesting that the 
low level of mutant virus replication in the chronic phase may have contributed to 
maintaining a high number of memory cells. 
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STATEMENT OF THESIS 
 
The first hypothesis tested in this thesis is that use of specific controlling elements 
in DNA vaccines will increase immunogenicity. An optimized vector will be used. The 
vector includes the Cytomegalovirus immediate early (CMV IE) promoter along with the 
CMV IE gene Intron A, and the tissue plasminogen activator (tPA) leader sequence 
replaces the HIV leader sequence. I postulate that this vector will yield better expression 
levels ‘in vitro’ and ‘in vivo’ ¾ as reflected by the specific antibody production against 
the antigen encoded in the vaccine. 
 
 The second hypothesis tested in this thesis is that codon optimization towards a 
mammalian bias of the gp120 sequence will enhance the immunogenicity due to 
increased protein expression levels from the DNA vaccine construct. 
 
The third hypothesis tested in this thesis is that directed mutagenesis in the DNA 
sequence of the HIV-1 gp120 V1 region will lead to the expression of partially non-
glycosylated antigens, thus creating a candidate for an engineered DNA vaccine against 
HIV-1. 
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EXPERIMENTAL APPROACH 
 
A successful DNA vaccine will require high levels of antigen expression. Codon 
optimization is meant to enhance protein synthesis in heterologous systems and to 
increase mRNA stability. HIV codon bias is distant from mammalian, which hinders 
expression levels in a mammalian system. Using chemical synthesis, it is possible to 
generate a DNA sequence encoding the same amino acid sequence as HIV gp120 but 
with a codon usage more similar to the well-characterized mammalian codon bias. The 
postulated increase in expression levels will expectedly yield higher antibody titers and 
better cell mediated immunity.  
 
In this thesis several sequence modifications have been devised to increase gp 120 
immunogenicity. Deglycosylation will be performed at particular sites on the gp120 V1 
loop in an attempt to create a DNA vaccine yielding an antigen with exposed conserved 
antigenic determinants. Some of the glycan moieties in gp120 are suspected of occluding 
conserved protein domains in an attempt to evade the immune system. Using directed 
mutagenesis, constructs will be made in which N-linked glycosylation sites are 
selectively removed without altering the conformation of gp120. This thesis will cover 
the production of the DNA vaccines, its administration to animal subjects, and 
characterization of the protein expressed ‘in vitro’.  
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MATERIALS AND METHODS 
 
Recombinant DNA techniques 
Polymerase Chain Reactions 
PCR reactions were performed using a MJ Research PTC-150 MinicyclerTM 
Thermocycler. Annealing temperatures for the primers were determined using Mac 
Vector software package, and were variable for the different reactions. Pfu polymerase 
was used for high fidelity amplification. After the reactions were complete, the PCR 
products were purified using the QIAquickTM PCR purification kit (see manufacturer’s 
manual for details). 
 
Plasmid DNA purification 
LB-Amp broth was inoculated with the desired culture and incubated overnight at 
37°C. Plasmid DNA was then extracted from the cultures using the Clontech 
NucleospinTM Mini-prep kit (see manufacturer’s manual for details). DNA was eluted 
from the columns in 50 ml of TE buffer or in distilled water if the next reaction was salt-
sensitive. 
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Agarose Gel Electrophoresis 
 Agarose was dissolved in TAE buffer to a 1% (w/v) concentration. The mixture 
was then heated in a microwave oven until the agarose was completely dissolved. A Bio-
Rad agarose gel casting system was used to pour the gel and after the agarose cooled 
down, samples were loaded with 4X loading buffer. The gel was run in a Bio-Rad gel box 
at approximately 50-70 Volts for one and a half to two hours.  After that, the gel was 
stained in an Ethidium Bromide solution (25 ng/ml in TAE buffer) for 20-30 min. The 
stained gel was then de-stained in TAE buffer for 20 min and a photograph was taken 
using a Kodak DC-40TM digital camera under UV light. 
 
Restriction Endonuclease Digestion 
The final volume for restriction enzyme digestions was 10 ml for analytical 
digestions and 30 ml for preparative digestions. The appropriate enzyme concentration 
and buffer, BSA, DTT, and DNA concentrations were estimated according to the New 
England BioLabs catalogue.  
 
Restriction Fragment Purification 
 After running an agarose gel, targeted DNA bands were cut and purified from the 
gel using the QIAquickTM gel extraction kit (see manufacturer’s manual for details). 
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Ligation 
 Appropriate amounts of prepared insert and vector were estimated from an 
agarose gel and added to a ligation reaction mix containing T4 ligase and ligase buffer in 
the amounts indicated in the Rôche catalogue. The reactions were run overnight at 16°C. 
 
Transformation 
E. coli HB101 competent cells were stored at -70°C, 100 ml/vial. The vial was 
thawed on ice. A certain amount of plasmid DNA or ligation mixture was added to the 
vial and mixed gently. The mixture was then incubated on ice for 30 min. Without 
mixing, the tube was removed and placed in a water bath at 42°C for 90 seconds. 400 ml 
of LB broth were added to each tube and incubated at 37°C for 45 min. After the 
incubation period, 100 and 300 ml of the transformation mixture were spread on different 
LB-Kan plates and they were allowed to incubate at 37°C overnight. The following day, 
colonies were picked for mini-prep analysis. 
 
SDS PAGE and Western Blots 
 
A 12 % Acrylamide/bis-acrylamide minigel was run with the supernatant and or 
lysate obtained from harvesting the transfected 293T cells, for approximately 2 hours at 
50 mA. Using a semi-dry blotting apparatus, the protein was transferred to a PVDF 
membrane for 1.5 to 2 hours at aproximately 80 mA per gel. The cut piece(s) of 
membrane were pre-treated by submerging it into methanol for 2 min, then it was 
transferred to ddH2O and washed, and finally it was soaked in transfer buffer. A cut piece 
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of 3MM WhatmanTM paper (soaked in transfer buffer) was placed on the anode of the 
blotting apparatus then the membrane, then the gel, then another piece of WhatmanTM 
paper. After the transfer was done, the membrane was incubated overnight in 15 ml of 
blocking solution (PBS, Tween-20 0.1-0.2% v/v, I-BlockTM 0.1% w/v) at 4° C. 
 
Antibody stocks were diluted to the desired concentration (1:200 for rabbit sera) 
in blocking solution. 5 ml of the diluted antibody were added to each membrane and it 
was allowed to incubate for 1 hour on the rotator at low speed. The membrane was then 
washed four times, 20 min each, with 15 ml of blocking solution, on the rotator at 
vigorous speed. The membrane was then incubated with the secondary antibody solution 
(diluted 1:5000 in blocking solution) for 1 hour, on the rotator at low speed. The 
membrane was then washed four times, 20 min each, with 15 ml of blocking solution, on 
the rotator at vigorous speed. 
 
Chemiluminescence was performed using the Tropix Western LightTM protein 
detection kit. Two pieces of thin, transparent plastic, big enough to cover the membrane 
were cut. 1.5 ml of substrate was added per membrane. The “sandwich” was allowed to 
incubate for 5 min. The membrane was dried on a paper towel, and transferred to a new 
dry sandwich. This was exposed in the darkroom for variable times. 
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DNA Tubing Preparation 
 
For all the procedures in this section, a Bio-Rad tubing prep station was used. 
Rislan tubing was dried for 1–2 hours by forcing N2 at ~ 0.2 L/min into the tubing. The 
ends of the tubing were capped after drying to keep moisture out. Water was added to 1 
µm gold beads (adjusted for each experiment) to achieve a final concentration of 100 
mg/ml. The gold beads were centrifuged to the bottom of a microcentrifuge tube for ~10 
seconds and the water was removed with a pipette, leaving a small amount of water (~50 
µl) in the tube. A 100 µl aliquot of spermidine (100 mg/ml in water) was added to the 
gold bead pellet, and the mixture was vortexed thoroughly at high speed until the gold 
was completely resuspended. Plasmid DNA was added to the beads/spermidine 
suspension. The mixture was vortexed only briefly on high, as the DNA can shear easily. 
CaCl2 (2.5 M in water) was added drop-by-drop into the mixture while vortexing at 
medium speed. The mixture was let stand at room temperature for 3-5 minutes to allow 
precipitation, and then centrifuged for 8 seconds, decanted and the supernatant was 
discarded. The coated gold beads were washed 5 times with 1ml dehydrated absolute 
ethanol. Each time, the ethanol-resuspended beads were centrifuged for 8-12 seconds and 
the supernatant removed. The beads were resuspended in the total volume of absolute 
ethanol needed for each preparation in a 20 ml glass scintillation vial and capped tightly. 
A piece of tubing 2 –3 inches beyond the right end of the tubing prep station was cut. A 
10 ml syringe was attached to the right end of the cut tubing. The glass vial of gold beads 
was sonicated briefly to completely suspend the beads, and the suspension was drawn 
into the tubing with a syringe. The gold was allowed to settle out of the suspension in the 
tubing for 10 minutes. Then the ethanol was slowly drawn from the tubing with the 
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syringe at a rate of about 2 inches per second. The tubing was connected to the nitrogen 
port and the prep station was turned on to rotate the tubing and spread the gold over the 
inside of the tubing for 1 minute. The nitrogen flow was turned on to 0.4 L/min to dry the 
remaining ethanol from the tubing for 5 minutes as it continued to rotate. The tubing was 
cut into half- inch cartridges using the tubing cutter, sealed in a scintillation vial with 
parafilm, and stored at –20oC. 
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Animal Groups for Immunization 
Rabbits 
New Zealand white syngenic rabbits were used to test the effect of 
deglycosylation on gp120 immunogenicity. 
Table I: Animal Groups and Immunizations Administered for the Rabbit 
Experiment. The table shows the composition of the vaccine formulation used to 
inoculate the rabbits in each group. dG: deglycosylated. 
 
Groups Rabbit # gp120 DNA vaccines rgp120 protein 
Group 11 C11-1,2 B B
Group 12 C12-1,2 B/dG1 B/dG1
Group 13 C13-1,2 Bal/dG1 Bal/dG1
Group 14 C14-1,2 Czm Czm
Group 15 C15-1,2 Czm/dG1 Czm/dG1
Group 16 C16-1,2 E/dG1 E/dG1
Group 17 C17-1,2 B, Bal, Czm, E B, Bal, Czm, E
Group 18 C18-1,2 (B, Bal, Czm, E)/dG1 (B, Bal, Czm, E)/dG1
Group 19 C19-1,2 (A2, B, Czm, D, E, F, G, Ba-l )/dG1 (B, Bal, Czm, E)/dG1
Group 20 C20-1,2 (A2, B, Czm, D, E, F, G, Ba-l )/dG1 (DNA boost)
Group 21 C21-1,2 vector (B, Bal, Czm, E)/dG1  
 
 
Table II: Immunization, bleeding and protein booster schedule for the rabbit 
experiment. 
 
Immunization Shedule
DNA vaccine I II III IV
Bleed I II III IV V VI VII VIII IX X XI XII
Protein Boost I II
Week 1 5 9 11 15 19 21 23 25 27 29 31
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Mice 
 
BALB/C syngenic mice were used to test the effect of codon optimization, intron 
A and leader sequence on gp120 expression levels.  
 
Table III: Animal groups for the mouse experiment. pJW4303 contains Intron A 
while pCMV12 does not. hiv represents HIV leader and tPA represents tPA leader. 
HXB2 is the lab-adapted strain gp120. Syn is the codon-optimized gp120 based on 
the JR-FL sequence. 
 
Groups DNA Vaccine mg DNA/animal No. of animals
A Vector 1 6 4
B Vector 2 6 4
C Intron A hiv.gp120.HXB2 6 4
D Intron A tPA.gp120.HXB2 6 4
E Intron A hiv.gp120.syn 6 4
F Intron A tPA.gp120.syn 6 4
G hiv.gp120.HXB2 6 4
H tPA.gp120.HXB2 6 4
I hiv.gp120.syn 6 4
J tPA.gp120.syn 6 4
 
 
Table IV: Immunization and bleeding schedule for the mouse experiment. 
 
 
Immunization Shedule
DNA vaccine I II III
Bleed I II III IV V VI VII
Week 1 5 9 11 13 17 21
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Anesthesia, Immunization and Bleeding 
 
Rabbits 
  A portion of skin was cleaned for the injection of anesthetic solution into the right 
hind leg quadriceps or lumbar muscle of each animal.  The anesthetic solution consisted 
of Ketamine (100 mg/ml)/Xylazine (100 mg/ml)/saline. The total volume of the 
anesthetic solution each animal received was calculated based on the animal’s weight 
(see table V). Rabbits were then bled from the central ear vein.  The backside of the ear 
was rubbed briskly with an alcohol prep.  Then, using a 23-gauge butterfly needle, blood 
was removed with a syringe until the desired amount was collected.  The blood was then 
transferred to a vacuum tube.  The animal’s abdomen was then shaved, and DNA-coated 
gold beads were inoculated to the shaved surface using the gene gun. Each animal 
received 36 mg of DNA per dose, and four doses were administered according to the 
schedule in table II.  
 
Table V: Dose and composition of the anesthetic solution injected to the rabbits 
Weight of rabbit (Kg)Dose of mixed Ket/Xyl (ml)Ketamine Xylazine
2.0-2.5 0.60 50.0 10.0
2.5-3.0 0.65 54.2 10.8
3.0-3.5 0.70 58.3 11.7
3.5-4.0 0.75 62.5 12.5
4.0-4.5 0.80 66.7 13.3
4.5-5.0 0.90 75.0 15.0
5.0 & up 1.00 83.3 16.7
Dosage/animal (mg)
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Mice 
 The abdominal fascia was rubbed with an alcohol prep, and 0.5-0.7 ml of 
anesthetic solution (Ketamine (100 mg/ml)/Xylazine (100 mg/ml)/Saline 4:1:10) was 
injected intraperitoneally using a tuberculin syringe. Once the animals were sedated, a 
glass capillary was used to draw blood from the periorbital cavity. The abdominal area 
was then shaved, and DNA-coated gold beads were inoculated using the gene gun. Each 
animal received 3 doses of 6 shots each according to the schedule in table IV. 
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ELISAs 
 
Concanavalin A Antigen Capture ELISA for Quantification of gp120  
96-well flat bottom plates were coated with 100 µl/well of Concanavalin A 
(ConA) at a concentration of 50 µg/ml in PBS, pH 7.4 and incubated for 1 hour at room 
temperature (RT). The plates were washed with wash buffer (PBS/0.1% Triton X-100) 5 
times: 3 times for 1 min, once for 5 min, and once for 15 min. 100 µl/well of PBS diluted 
gp120 antigen were added in duplicate, serial dilutions were performed, and the plates 
were allowed to incubate for 1 hour at room temperature (RT). After that the plates were 
washed as above. Free ConA binding sites were blocked with 200 µl/well of blocking 
buffer, and incubated for 1 hour at RT. The plates were washed as above. 100 ml of anti-
gp120 rabbit sera at 1:5000 dilution in whey dilution buffer (PBS/4% whey/0.5% Tween-
20) were added to each well and allowed to incubate for 1 hour at RT. The plates were 
washed as before. 100 ml of biotinylated anti-rabbit IgG at 1:1000 in whey dilution buffer 
were added to each well and allowed to incubate for 1 hour at RT. The plates were 
washed again. 100 ml of streptavidin-conjugated horseradish peroxidase (HRP-
streptavidin) at 1:2000 in whey dilution buffer were added to each well, and allowed to 
incubate for 1 hour at RT. The plates were washed as above. Fresh TMB substrate (1 
TMB tablet/0.05 M phosphate/citrate buffer/0.006% H2O2) was prepared, and 100 ml 
were added to each well allowing 3.5 min incubation time at RT.  The reaction was 
stopped by adding 25 ml of 2M H2SO4 to each well, and the OD was read at 450 nm using 
a Dynex Opsys MRTM plate reader. 
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With this assay (the Antigen Capture ELISA for Quantification of gp120) the 
antigen concentration was normalized, using a serum raised by polyvalent gp120 
immunization, to give an equal concentration.  
 
Concanavalin A Antigen Capture ELISA for Detection of Antibody 
96-well flat bottom plates were coated with 100 µl/well of Concanavalin A at a 
concentration of 50 µg/ml in PBS, pH 7.4 and incubated for 1 hour at room temperature 
(RT). The plates were washed with wash buffer 5 times: 3 times for 1 min, once for 5 
min, and once for 15 min. 100 µl/well of PBS diluted normalized gp120 antigen 
(concentration normalized with the Antigen Capture ELISA for Quantification of gp120) 
at around 1 ug/ml were added and allowed to incubate for 1 hour at room temperature. 
After that the plates were washed as above. Free ConA binding sites were blocked with 
200 µl/well of blocking buffer (5% non-fat dry milk in whey dilution buffer) and 
incubated for 1 hour at RT. The plates were washed as above. 100 ml of anti-gp120 rabbit 
sera at 1:5000 dilution in whey dilution buffer were added to the wells, serial dilutions 
were performed, and the plates were allowed to incubate for 1 hour at RT. The plates 
were washed as before. 100 ml of biotinylated anti-rabbit IgG at 1:1000 in whey dilution 
buffer were added to each well and allowed to incubate for 1 hour at RT. The plates were 
washed again. 100 ml of streptavidin-conjugated horseradish peroxidase (HRP-
streptavidin) at 1:2000 in whey dilution buffer were added to each well and allowed to 
incubate for 1 hour at RT. The plates were washed as above. Fresh TMB (1 TMB 
tablet/0.05 M phosphate/citrate buffer/0.006% H2O2) substrate was prepared and 100 ml 
were added to each well allowing 3.5 min incubation time at RT.  The reaction was 
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stopped by adding 25 ml of 2M H2SO4 to each well and the OD was read at 450 nm using 
a Dynex Opsys MRTM plate reader. 
 
 
Setup of Murine Splenocytes for Cell Mediated Immune Response Assays 
 
 
Mice were anesthetized and then euthanized by cervical dislocation. The 
abdominal fascia was flooded with 70% ethanol, then a transversal 1 cm midline incision 
was made and torn open. The spleen was then removed and placed in ~10 ml of medium 
(RPMI 1640 complete 10% heat- inactivated FBS 1% Penicillin-Streptomycin). The 
spleen-containing media was placed over a sterile platinum screen tissue sieve with a 
petri dish underneath, and the spleens were pressed through the screen using a sterile 
spatula. The homogenate was then pipetted into a 50 ml conical tube. 10 more ml of 
media were used to rinse the petri dish, and the suspension was added to the same tube. 
The tube was then centrifuged at 1,500 rpm, and the supernatant removed. The pellet was 
washed with 10 ml of media. Media was removed and the pellet was resuspended in 8 ml 
of ACK lysis buffer (NH4Cl 16.58 g, KHCO3 2 g, EDTA-Na2 14.4 mg, dH2O 200 ml). 
This was allowed to stand for 2-3 min and spun down at 1,500 rpm. The supernatant was 
removed and the pellet was washed twice with 20 ml media. The supernatant was 
removed and a final aliquot of 10 ml of media was used to resuspend the pellet and 
clumps were removed. Viable cells were counted under the microscope. The cell 
suspension was diluted with media to a stock concentration of 5x106 cells/ml. 
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ELISPOT Assay for Detection of IFN-g  Production by Murine Splenocytes 
 
Plates (96 well multiscreen Immobilon-P-membrane sterile white plate, Millipore) 
were coated overnight at 4°C with 100 ml/well capture antibody (purified rat anti-mouse 
IFN-g: Rat IgG1, clone R4-6A2 PharMingen 1mg/ml) at a final concentration of 5 mg/ml 
in PBS. The plates were then rinsed thrice with sterile PBS, and then blocked with 200 
ml/well complete RPMI 1640 (10% heat inactivated FBS 1% Penicillin-Streptomycin) for 
two hours at 37°C. The different peptides used for stimulation were mixed with an 
appropriate splenocyte amount for each of the mouse groups to a final peptide 
concentration of 4 mg/ml, and cell concentrations of 0.5 x106 and 0.1x106 cells/ml. Con A 
(50 mg/ml in PBS) was used as a positive control instead of peptide, at a final 
concentration of 2 mg/ml. A volume of 100 ml of the splenocyte suspension mixed with 
peptide or ConA was added to each well. Plates were incubated 24 hours at 37°C and then 
rinsed twice with sterile distilled water. Plates were washed 6 times with PBS/0.05% 
Tween 20. Detection antibody (Biotin-conjugated rat anti-mouse IFN-g: Rat IgG1, clone 
XMG1.2 PharMingen 0.5mg/ml) was diluted to a final concentration of 1.25 mg/ml in 
PBS/0.005% Tween 20/5% FBS and 100ml were added to each well. Plates were 
incubated overnight at 4°C. Plates were washed six times with PBS/0.05% Tween 20. 
Alkaline peroxidase-conjugated Streptavidin (AP-conjugated streptavidin, PharMingen) 
was diluted 1:800 in PBS/0.005% Tween 20/5% FBS, and 100 ml were added to each 
well and then allowed to incubate at 37°C for 30 min. The plates were washed 8 times 
with PBS/0.05% Tween 20. 100 ml of pre-filtered substrate (AP Substrate 1-STEP 
NBT/BCIP, PIERCE) were added to each well and the plates were allowed to incubate at 
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room temperature for 6-8 min, and then washed thoroughly under tap water and allowed 
to air-dry completely. Dark-blue spots were counted under a dissecting microscope and 
the results recorded. 
 
 
Molecular Cloning of Vaccine Constructs 
 
Deglycosylated Vaccine Constructs 
For the deglycosylated constructs, the appropriate inserts were amplified by PCR 
from plasmids containing the gp140 gene for every clade (Gao et al., 1996), and 
subcloned into pSW3891 vector (figure 2). Mutagenic primers were used in which 
mismatches were introduced creating Glutamine to Asparagine substitutions. New 
restriction sites were also generated to facilitate screening by introducing mismatches in 
the same primers (table VII). Analytic digestions were performed to check for the correct 
insertion (see figure 5).  
 
The animals were vaccinated with constructs encoding the mutant form of gp120. 
There are several potential N-linked glycosylation sites, i.e. sites where the canonical N-
linked glycosylation sequence is found (N-X-S/T). Mutations were introduced at some of 
these sites by changing the Asparagine residue to Glutamine, a residue similar to 
Asparagine in biochemical properties, but that cannot be glycosylated. These mutations 
targeted the tips of the V1 loop, the region that is believed to be most important in 
epitope occlusion. Table VI shows the positions in the gp120 V1 region that were 
subjected to the deglycosylation mutations. 
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Figure 2: Vector pSW3891. Note the presence of the CMV IE promoter, Intron A, tPA 
leader sequence, and Bovine Growth Hormone Polyadenylation signal (BGH) 
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Table VI: Different deglycosylated constructs generated by directed 
mutagenesis. The table shows the relative positions of the V1 loop for each clade, 
the potential glycosylation sites in V1 and the glycosylation sites that were 
actually mutated. 
 
Construct Name  Vector Insert 
V1 
Loop 
Position 
in env 
No. of aa 
in V1 
loop 
Potential N-linked 
Glycosylation sites in 
V1 Region 
N®Q 
Mutations in 
the Modified 
Constructs 
pSW3891/gp120.A2/dG pSW3891 HIV-1 gp120 A2 128-153 24 N131, 135, 142, 152 N131, 134, 141 
pSW3891/gp120.Bal/dG pSW3891 HIV-1 gp120 Bal 130-160 29 N129, 135, 140, 143, 159 N135, 140, 143 
pSW3891/gp120.B/dG pSW3891 HIV-1 gp120 B 128-159 30 N127, 133, 136, 140, 143, 158 N133, 136, 140 
pSW3891/gp120.C1/dG pSW3891 HIV-1 gp120 C1 128-149 20 N130, 137, 148 N130, 137 
pSW3891/gp120.CZM/dG pSW3891 HIV-1 gp120 CZM 128-156 28 
N132, 138, 143, 144, 
149 N143, 144, 149 
pSW3891/gp120.D/dG pSW3891 HIV-1 gp120 D 128-147 20 N127, 132, 136, 146 N132, 136  
pSW3891/gp120.E/dG pSW3891 HIV-1 gp120 E 135-161 25 N134, 137, 142, 146, 153, 160 N137, 142, 146 
pSW3891/gp120.F/dG pSW3891 HIV-1 gp120 F 128-156 27 N134, 137, 143, 155 N134, 137, 143 
pSW3891/gp120.G/dG pSW3891 HIV-1 gp120 G 128-152 23 N130, 134, 140, 151 N130, 134, 140 
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Table VII: Mutagenic primers used to introduce deglycosylation mutations in 
gp120. Characters in italics denote changes from the original sequence. 
Characters in bold case represent the mutations in the Asparagine residues 
changing to Glutamine. Paired primers were GP120-p-B1 for the forward primers 
and GP120-p-F1 for the backward primers (see text below). 
 
Clade Primer name Position Sequence 
GP120-19; 
Forward 405-436 
AAT ATC ACG AAT TCT ATC ACC CAG AGC TCA G 
           EcoR I A2 
(92UG037) GP120-20; 
Backward 422-388 
GAT GGA ATT CGT GAT CTG ATT GGT GAT CTG ATA GC 
      EcoR I 
GP120-3; 
Forward 438-461 
gg ACT AGT AGT GAG ACA ATG ATG GAG GAG   
    SpeI B 
(92US715.6) GP120-4; 
Backward 
436-402 gg ACTA GT GGT CTG AGT AGC CTG CCT CGT GGT CTG AGT ATC     SpeI 
GP120-17; 
Forward 774-810 
AAT GCT ACT AAT GGC CAG GAC ACT CAG ACC ACT AG 
               Msc I 
Bal 
GP120-18; 
Backward 800-765 
ATT AGT GTC CTG GCC ATT AGT AGC CTG CCT CAA ATC 
               Msc I 
C1 
(92BR025) 
GP120-9; 
Forward 375-418 
ACG TTA CAC TGC AGT CAG AGA ACT ATT GAC TAC AAT CAG AGA 
AC          Pst I             
GP120-27; 
Forward 337-371 CAG CAG ACC ACC AAC GTG CAG AAC AGC ATG AAC GG C 
(ZM651) GP120-28; 
Backward 336-307 CAC CAC GCT GTT CTG CAC GTT GCG GGT CAC  
GP120-21; 
Forward 393-428 
TGG AAG CAG GCC TCT ACT CAG GCC ACT AAT GAG GGC 
          Stu I D 
(92UG021) GP120-22; 
Backward 416-383 
GGC ATT AGT GGA GGC CTG CTT CCA TTC AGT GCA G 
                Stu I 
GP120-13; 
Forward 
411-449 AAT TTG ACC AAT GGC CAG AAG ACA ACT CAG GTC TCT AAC                 Msc I E 
(93TH976) GP120-14; 
Backward 437-395 
AGT TGT CTT CTG GCC ATT GGT CAA CTG GGT ACA AAT C  
               Msc I 
GP120-15; 
Forward 405-438 
GGC ACC AAT GAC ACG ATC GCC ACC CAG GAC AGC C 
                  Pvu I F 
(93BR020) GP120-16; 
Backward 434-396 
GTC TTA GGT GGC GAT CGT GTC CTG GGT GCC CTG GGT GGC 
               Pvu I 
GP120-11; 
Forward 402-434 
CAG TAT ACT GAG CTC GCT CAG ACA AGC ATT GGG 
             Sac I G 
(92UG975) GP120-12; 
Backward 425-383 
TGT GTT AGC GAG CTC AGT ATA CTG GTT GGT TAC CTG AGC ACA 
G            Sac I 
 
  
For all the reactions, forward primers were used in combination with the GP120-
p-B1 primer, which hybridizes in the 5’ region of the gp140 template plasmids. 
Backward primers were used with the GP120-p-F1 primer, which hybridizes in the 3’ 
region of the gp140 template plasmids. 
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The deglycosylated constructs prepared in this thesis were the ones corresponding 
to clades A2 and G; different researchers at the Laboratory of Nucleic Acid Vaccines 
prepared the rest. 
 
Cloning of the gp120.A2 deglycosylated form was performed as follows: the 
vector pSW3891 was digested with Bam HI, purified with the QIAGEN PCR purification 
kit, and then digested again with Pst  I. After another round of purification, Calf Intestinal 
Phosphatase (CIP) treatment was performed, and the vector was purified a final time. For 
the insert, two PCR rounds were performed, using as a template the wild-type gp120 
form of the respective clade in the pJW4303 vector. Each of the reactions used a 
mutagenic primer (see list above) and a paired primer hybridizing with the pJW4303 
vector sequences flanking the wild-type gp140 insert. The 5’ PCR product (obtained with 
the first mutagenic primer and the GP120-P-B1) was digested with Eco RI and Pst I. The 
3’ PCR product (obtained with the second mutagenic primer and the GP120-P-F1) was 
digested with Eco RI and Bam HI.  
  
Cloning of the deglycosylated gp120.G form was performed in a similar way: the 
vector pSW3891 was digested with Bam HI, purified, and then digested with Pst  I and 
purified again. CIP treatment was performed, and the digested vector was purified a final 
time. For the insert, two PCR rounds were performed, using as a template the wild-type 
gp120 form of the respective  clade in the pJW4303 vector. Each of the reactions used a 
mutagenic primer (see list above) and a paired primer hybridizing with the pJW4303 
vector sequences flanking the wild-type gp140 insert. The 5’ PCR product (obtained with 
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the first mutagenic primer and the GP120-P-B1) was digested with Sac I and Pst I. The 3’ 
PCR product (obtained with the second mutagenic primer and the GP120-P-F1) was 
digested with Sac I and Bam HI. After purification, an analytic gel was run to estimate 
the insert and vector concentrations and the ligation reaction was set up. The next day, 
the ligation mixture was used to transform competent cells, which were spread on Kan 
agar plates and the transformants screened. 
 
This cloning strategy provides directionality as well as the introduction of a 
unique restriction site in the insert, making it easier to check for the correct clones 
through analytic digestions of the transformants obtained. 
 
Vaccine Constructs Used in the Mouse Experiment 
The clones used in the mouse experiment were obtained from Allison Hirsh 
(UMass Medical School). In figure 3, the construct arrangement is shown. The vectors 
used had no leader sequence, and the CMV IE promoter was present with or without 
intron A. The leader sequence cloned upstream the gp120 gene was either the HIV leader 
or the tPA leader. The amino acid sequence of each of the leader sequences used is 
shown in table VIII. The inserts were cloned into the vector’s Hind III and Bam HI sites 
downstream from the CMV IE promoter and upstream from the BGH poly A site. 
 
Table VIII: amino acid sequences of the signal peptides encoded in the constructs. 
Positively charged amino acids are shown in bold case. 
 
Signal Peptide  Sequence 
Tissue Plasminogen Activator MDAMKRGLCCVLLLCGAVFVS 
HIV-1 env  RSKLMRVKEKYQHLW RWGW RWGTMLLGMLMICASGA  
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Figure 3a: eight constructs were used in the mouse experiment: with or without intron A, 
with tPA leader or HIV leader, and with codon optimization (syn) or without codon 
optimization (HXB2). 
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Figure 3b: Vectors used in the construction of the mouse experiment vaccine constructs. 
CMV IE gene Intron A is provided only by pJW4303. 
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RESULTS 
 
Mouse Experiment: Antigen Optimization. Effects of Codon Optimization, 
tPA leader and Intron A 
 
 In this experiment the objective is to compare the immune response obtained from 
constructs differing in three variables: codon bias, leader or signal sequence, and 
spliceability. The effect of these variables on ‘in vitro’ and ‘in vivo’ expression has been 
tested in the past (Huang and Gorman, 1990; Chapman et al., 1991; Cheng et al., 1993; 
Luo and Reed, 1999; Kotsopoulou et al., 2000; Xu et al., 2001). Here, an immunological 
approach is provided, in which the importance of each of these elements is evaluated by 
measuring the immunogenicity of the different DNA vaccine constructs.  
 
 Two gp120s were tested, one codon-optimized, based on the amino acid sequence 
of the JR-FL strain. The other is a non-codon-optimized strain, HXB2. Both are members 
of the B clade, nevertheless, the optimal situation would have been to have a codon-
optimized gp120 construct derived from the same strain as the non-codon optimized 
construct. This would allow for a stronger comparison, but this was not possible due to 
availability reasons. To circumvent this problem, both HXB2 and JR-FL (synthetic, syn) 
sera were tested against the homologous and heterologous antigens.  
 
A codon usage comparison was made to proof that the codon usage of the codon-
optimized construct was indeed closer to human genes, and that the codon usage of both 
HXB2 and non-optimized JR-FL HIV clones was similar. As seen in table IX, in 76 % of 
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the cases (16 out of 21 possible cases) codon usage for a given amino acid showed a clear 
pattern: HIV and JR-FL clustered together and syn and human clustered together in a 
different group. 
Table IX: Codon usage comparison. Two HIV codon usage patterns (HXB2 
& JR-FL), the codon-optimized codon usage pattern (syn), and the human Factor 
VII gene usage pattern (human) are compared. A percentage of the number of 
times a particular gene uses a determinate codon to code for a given amino acid 
is shown. The highest percentage for every gene and for every aminoacid is 
shaded. 
 
HXB2 JR-FL syn Human
AA   Percent Percent Percent Percent
TT T   F 2.5 1.7 0.7 0.2
TT  C   F 1.3 1.2 2.4 2.3
TT  A   L 1.9 2.2 0 0.4
TT G   L 0.8 1.9 0.2 0.6
TC  T   S 0.6 0.8 1.4 0.5
TC  C   S 0.6 0.4 0.7 2.2
TC A   S 1.7 1.2 0.2 1.5
TC G   S 0 0.2 0 0.1
TA T   Y 2.1 1.9 0.7 0.7
TA  C   Y 0.2 0.8 1.5 1.2
TA A   * 0 0.1 0 0.1
TA  G   * 0 0 0.2 0.6
TG T   C 3.2 1.9 1.2 1.6
TG  C   C 0.6 0.7 2.4 3.7
TG  A   * 0 0 0 0.4
TG  G   W 2.1 3.2 1.9 2.2
CT  T   L 0.4 0.8 0.5 0.7
CT  C   L 0.4 1.7 0.5 2
CT  A   L 1.1 1.5 0.5 0.1
CT  G   L 1.1 1.8 6.2 4.6
CC T   P 0.4 0.6 2.1 1.1
CC  C   P 1.3 0.9 3.3 2.2
CC A   P 2.5 1.7 0.5 1.6
CC  G   P 0.2 0.2 0.3 0.5
CA T   H 1.3 0.8 0.3 0.4
CA  C   H 0.2 0.5 1.5 5.4
CA  A   Q 2.1 2.1 0.3 1.2
CA  G   Q 1.7 2.5 3.4 4
CG  T   R 0.2 0.1 0.2 0.1
CG C   R 0 0.2 0.3 1.3
CG  A   R 0 0.1 0 0.5
CG  G   R 0 0.1 0.2 1.7
Codon
HIV Human
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Table IX (continued) 
 
HXB2 JR-FL syn Human
AA   Percent Percent Percent Percent
AT  T   I 2.5 2.6 1.7 1
AT  C   I 1.7 1.2 4.6 2.2
AT  A   I 3.4 3.9 0.2 0.5
AT G   M 1.9 1.9 2.1 2.1
AC  T   T 2.1 1.9 2.1 0.7
AC  C   T 1.9 1.8 5.3 1.5
AC A   T 4.4 2.8 0.3 3.2
AC  G   T 0.6 0.6 0 1.7
AA  T   N 6.5 5.3 2.2 0.7
AA  C   N 2.3 1.7 5.3 1.5
AA  A   K 4.4 3.4 0.2 0.9
AA  G   K 2.1 1.5 5.2 2.1
AG T   S 3 1.8 0.2 0.5
AG  C   S 1.9 1.2 3.4 1.7
AG A   R 3.8 4 0.2 3.3
AG  G   R 0.4 1.5 4.3 1.2
GT T   V 0.6 0.7 0 0.4
GT  C   V 1.1 1.1 0.7 2
GT  A   V 4.4 3.4 0.2 0.4
GT  G   V 1.1 1.7 6.4 2.6
GC  T   A 0.6 1.8 1.4 1
GC  C   A 1.1 1.1 3.4 2.2
GC  A   A 2.3 2.2 0.3 2
GC  G   A 0.2 0.4 0 1.1
GA  T   D 2.5 2 1.2 1.8
GA C   D 1.5 1.5 2.6 2.8
GA A   E 3.2 4.8 0 1.1
GA  G   E 1.7 1.7 6.2 4.3
GG  T   G 0.8 0.8 1.7 0.2
GG  C   G 0.2 0.7 3.3 3.7
GG  A   G 3.6 3.7 0 1.6
GG  G   G 1.5 1.7 1.7 2.6
Codon
HIV Human
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‘In vitro’ Expression 
In vitro expression was assayed. Western blots were run to compare the in vitro 
expression of the different constructs, and how the encoded protein was distributed in the 
intracellular and secreted fractions. This kind of comparison will give a first insight into 
the effect of the leader sequence on secretion, which is a determinant factor in the 
efficacy of the vaccine to raise a humoral immune response. The in vitro expression 
analysis will also reveal whether codon optimization and the presence of intron A 
actually contributed to increasing the overall expression levels. As seen in figure 4, the 
constructs with codon optimization had a higher overall expression as compared to the 
non codon-optimized constructs (HXB2). It is also remarkable that the expression falls 
dramatically in the non codon-optimized (HXB2) constructs when tPA and/or intron A 
are not present. To draw any conclusions from the distribution of the protein in 
supernatant and lysates, it is necessary to note that the lysate fraction is more 
concentrated than the supernatant, and that there is not an easy method to equalize the 
gp120 amount loaded from each fraction. For this reason, the comparisons should be 
made between the same fraction for two different constructs, e.g. compare the amount of 
protein present in the lysate of the codon-optimized construct with tPA with the amount 
of protein in the lysate of the codon-optimized construct without tPA. Following this rule, 
it is noticeable that secretion is augmented when tPA leader is included, especially when 
we look at the codon-optimized (syn) constructs. The band corresponding to the 
supernatants of the synthetic constructs with tPA (lane 5 panel A, and lane 5 panel B) is 
thicker than the same band for the constructs without tPA (lane 9 panel A, and lane 9 
panel B). And the opposite effect is seen for the lysates (lane 6 panel A, and lane 6 panel 
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B, compared to lane 10 panel A, and lane 10 panel B). It is also noticeable that the lysates 
of the constructs without tPA leader (lane 10 panel A, lane 10 panel B) appear as a 
blurred band, probably due to misfolding or truncation of the nascent protein. 
 
 
 
Figure 4: ‘In vitro’ expression of the mouse experiment constructs. 293T cells were 
transfected with the different DNA vaccine constructs. Cell supernatants and lysates 
were collected and analyzed by western blot. Panel A corresponds to the constructs with 
intron A (pJW4303 vector), and panel B corresponds to the constructs without intron A 
(pBC12/CMV vector). The arrows indicate the position of gp120, although it can vary due 
to differences in glycosylation. 
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ELISA 
 As a measure of the specific antibody response mounted by the mice after being 
inoculated with the DNA vaccines, ELISAs were performed to quantitate the levels of 
anti-gp120 antibodies. Since the antigens encoded were slightly divergent in sequence, 
homologous and heterologous reactivity was measured. Each serum was tested against 
the same antigen used to immunize the mouse from which the serum was collected 
(homologous reactivity), and against the other antigen used in the experiment 
(heterologous reactivity). The results are shown in figure 5. 
 
 Overall, the codon optimized JR-FL (syn) construct had the highest reactivity. In 
the upper left panel (figure 5) it is shown how the reactivity decreased only slightly when 
intron A was not present, and a little more when the construct had the HIV leader 
sequence (tPA-) instead of the tPA leader sequence (tPA+). The effect of intron A was 
practically inconspicuous for the synthetic constructs, since the four curves clustered in 
two groups, two with tPA leader and two with HIV leader. In the upper right panel, the 
homologous reactivity for the HXB2 (non codon-optimized) constructs is shown. In this 
case, the presence of the tPA leader sequence also had an effect, only this time it was 
more dramatic. Intron A was required for the HXB2 constructs to show reactivity; even 
the construct with tPA leader but without intron A showed no reactivity.  
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 As seen in the lower panels, heterologous reactivity was lower, consistent with the 
slight sequence divergence, although the pattern showed no major change. The exception 
was the reactivity of the antiserum from the mice immunized with the non-codon 
optimized (HXB2) gp120 with tPA and without Intron A construct, against the codon-
optimized (syn) antigen (see figure 5, lower left panel). In this case the heterologous 
reactivity was higher than the homologous reactivity (see figure 5 upper right panel). 
 
Figure 5: ELISA data for the mouse experiment. Antigens were produced from the DNA 
vaccine constructs by transfecting 293T cells. Each antigen, gp120.syn or gp120.HXB2 
was used to coat two plates. The upper panels show the homologous sera reactivity, 
and the lower panels show the heterologous sera reactivity. OD at 450 nm was used as 
a measure of specific reactivity. 
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 The time course of the humoral response was analyzed by ELISA. Only the 
groups that showed highest reactivity for each gp120 in the previous assay were analyzed 
(see figure 5). As it is shown in figure 6, the specific reactivity and the antibody titers 
were higher for the optimized JR-FL (syn) gp 120 constructs with intron A and with tPA 
leader than for the synthetic gp 120 with intron A but without tPA leader. Although at 
different levels, the response for both constructs followed the same pattern along time. 
Both the specific reactivity and the titer started showing from week 4 (after the first 
immunization), grew rapidly up to week 10 (after the third and last immunization), and 
remained stable up to week 12. Therefore, the humoral immune response observed was 
sustained for the animals immunized with these constructs. For the two HXB2 (non-
codon optimized) constructs, the initial response was stronger (week 4, after first 
immunization), but it decreased with time. For the construct without Intron A, the 
response was not sustained and it decreased after the second immunization (week 8). 
 
 
Figure 6: Time course of antibody reactivity and titer for the mouse experiment during 12 
weeks after the first imunization. The left panel shows the ELISA reactivity against time. 
The right panel shows the antibody titers against time. The titer is measured as the 
inverse of the dilution indicated on the axis.  
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 The subsequent figures (7, 8, and 9) were generated from the same set of data as 
figure 5. The data are rearranged to emphasize the effect of the three individual 
modifications: intron A (figure 7), codon optimization (figure 8) and tPA leader (figure 
9). 
 
Figure 7: Role of encoded intron A in the antibody response obtained. The left panel 
shows specific antibody reactivity against codon-optimized constructs (syn) with or 
without intron A. The right panel shows specific antibody reactivity against non codon-
optimized constructs (HXB2) with or without intron A.  
 
 
 
Figure 8: Effect of codon optimization. Autologous reactivity of sera from animals 
immunized with constructs without tPA and intron A, and with or without codon 
optimization. 
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Figure 9: Effects of tPA leader sequence on the antibody response. The left panel shows 
specific antibody reactivity for sera from animals immunized with constructs encoding 
HXB2 (non codon-optimized) gp120 with intron A, and with or without the tPA leader 
sequence. On the right panel the same effect is shown for sera from animals immunized 
with codon-optimized constructs with or without tPA, and regardless of the presence of 
intron A. 
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ELISPOT 
Mice were terminated and splenocytes were collected after the third immunization 
and after boosting with DNA one week prior to termination. They were stimulated in 
vitro with different peptides. The B peptides are based on the B clade and were expected 
to be cognate to the synthetic constructs, since these constructs were derived from the JR-
FL strain, a clade B member. The HXB2 peptides are derived from the HXB2 IIIB strain 
of HIV-1, also a clade B member, and have been proven to be T-epitopes for gp120 
HXB2 (Takeshita, et al., 1995). The results in table X indicate a high IFN-g production 
from the splenocytes of the mice immunized with the HXB2 (non-codon-optimized) 
construct with tPA leader and Intron A, after stimulation with the HXB2 IIIB peptides. 
The rest of the constructs show very low ?  probably background ?  reactivity. The 
ELISPOT assays were thus inconclusive, since the clade B peptides were not able to 
stimulate splenocytes from the mice immunized with the optimized JR-FL (denoted as 
‘syn’) gp120 construct. 
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Table X: ELISPOT results. The splenocytes from the mice immunized with the 
different constructs were tested for specific IFN-g production after stimulation with 
homologous and heterologous peptides (see text above). Spots were counted per 
million cells. 
 
Peptide: None
B V3 
9-mer
B V3 
15-mer
HXB2 IIIB 
9-mer
HXB2 IIIB 
15-mer
Vaccine Construct
HXB2 Intron A+ tPA+ - - - 920 240
HXB2 Intron A+ tPA- - - - 20 80
syn Intron A+ tPA+ - - - 60 80
syn Intron A+ tPA- - 60 40 20 -
HXB2 Intron A- tPA+ - 40 40 40 -
HXB2 Intron A- tPA- - - - - -
syn Intron A- tPA+ - - - - -
syn Intron A- tPA- - 40 60 20 40
Con A Positive control 1160 - - - -  
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Rabbit Experiment: Epitope Exposure. 
Molecular Cloning and Characterization of Deglycosylated gp 120 Vaccine 
Constructs 
 
 
 This experiment is to construct DNA vaccines in which the N-linked 
glycosylation sequence is mutated by substituting the Asparagine residue by a Glutamine, 
therefore removing the N-linked glycan at that particular site. Deglycosylation mutations 
were introduced by directed mutagenesis at particular sites in the tip of gp120’s V1 loop, 
the area where glycosylation is suspected to be covering conserved epitopes. In figure 10 
an alignment of the amino acid sequence covering the V1/V2 region of all the different 
clades is shown. The potential glycosylation sites in V1 are highlighted. Based on the 
structure of gp120 (figure 1), and on this alignment (figure 10), a pattern can be inferred 
for the glysosylation sites.  There are N-linked glycosylation sites required for proper 
folding of the protein at either sides of the highly variable loop area. These N-linked 
glycosylation sites are located near cysteine residues involved in disulfide bond 
formation. These residues were left intact, since modifications in these residues will 
probably result in protein misfolding. The residues targeted in this thesis are located in 
the highly variable area of the V1 loop tip. 
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Clustal W(1.4) multiple sequence alignment 
 
11 Sequences Aligned.         Alignment Score = 12363 
Gaps Inserted = 23            Conserved Identities = 15 
 
Pairwise Alignment Mode: Slow 
Pairwise Alignment Parameters: 
    Open Gap Penalty = 10.0   Extend Gap Penalty = 0.1 
    Similarity Matrix: blosum 
 
Multiple Alignment Parameters: 
    Open Gap Penalty = 10.0   Extend Gap Penalty = 0.1 
    Delay Divergent = 40%     Gap Distance = 8 
    Similarity Matrix: blosum 
 
Processing time: 0.6 seconds 
 V1 loop V2 loop 
 
     
gp120.A1 128                         CNATASNVTNEMRN C SFNITTELKDKKQQVYSLFYKLDVVQINE-K-----NETDKYRLINC 184 
gp120.A2 128 CSYNITNNI------TNSITNSSVNMREEIKN C SFNMTTELRDKNRKVYSLFYKLDVVQINNGN-----NSSNLYRLINC 197 
gp120.Bal 130     LNCTDLRNATNG--NDTNTTSSSREMMGGGEMKN C SFKITTNIRGKVQKEYALFYELDIVPIDN-------NSNNRYRLISC 203 
gp120.B 128 CTNLRNDTNTTRNATNTTSS-ETMMEEGEIKN C SFNITTSIRDKVQKEFALFYKLDVVPIEN-------DTTS-YRLISC 199 
gp120.C1 128 CSNRTIDYN-----------NRTDNMGGEIKN C SFNMTTEVRDKREKVHALFYRLDIVPLKNESS----NTSGDYRLINC 193 
gp120.C2 128 CTNANGTNN-------NGTVNVNDTMYGEIKN C SFNMTTELRDKKKQVYALFYKLDIVSLNENS-----NNSSEYRLINC 196 
gp120.CZM  128 CTEVNVTRNVN-NSVVNNTTNVNNSMNGDMKN C SFNITTELKDKKKNVYALFYKLDIVSLNETDDSETGNSSKYYRLINC 207 
gp120.D 128 CTEWKNATTN------------ATNEGIGMKN C SF---TEVRDKKKQAYALFYKLDVVQMNDDN-----STNTSYRLINC 188 
gp120.E 135CTNATLNCTNLTNGNK------TTNVSNIIGNLTDEVRN C SFHMTTELRDKKQKVYALFYKLDIVQIN----------SSEYRLINC 206 
gp120.F 128 CRNIATNGTN----DTIATNDSLKEDPWAIQN C SFNTTTEIRDKQLKVHALFYKLDIVLINQ-------NDNRTYRLIHC 197 
gp120.G 128 CANVTNNYT--------ELANTSIGNREEIKN C SFKVTTELRNKQKEEYALFYRTDVIPINDNSKS-SASNYSDYRLINC 199 
 
Consensus  CTN . . N                   EIKN C SFN.TTELRDK..KVYALFYKLDIV INN            YRLINC 
 
Figure 10: Clustal W alignment of the V1/V2 regions of gp120 in different HIV-1 clades. 
The dashes represent gaps. Asterisks represent highest homology, and dots represent a 
lower degree of homology. The parameters of the alignment are shown on top. The 
highly variable regions correspond to the tips of the V1 and V2 loops. The Asn residues 
susceptible to N-linked glycosylation in the V1 loop are highlighted. 
 
 
Molecular Cloning 
In figure 11 a map is shown of the deglycosylated gp120 clade G vaccine 
construct. Two segments are cloned into the Pst I – Bam HI fragment of the vector. Each 
of the segments is a digested PCR product from each of the two PCR reactions conducted 
to generate the mutations. The Sac I site in between the two segments was introduced 
with the PCR primers to facilitate screening. 
.  
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Figure 11: map of one of the deglycosylated constructs obtained, the deglycosylated 
gp120 clade G. Note the presence of the newly introduced Sac I site. 
 
 The transformants were screened by restriction digestion, and in the selected 
clones the sizes obtained after analytic digestions coincided with the expected sizes, as 
shown in figure 12. 
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Figure 12: Analytic digestions were performed for the deglycosylated gp120.G clone 
(pSW3891/gp120.GdG1) to check for the correct sizes before testing expression. Lane 
1: uncut plasmid. Lane 2: Bam HI, Lane3: Bam HI + Nhe I, Lane 4: Sac I, Lane 5: 1 Kb 
ladder. Fragment size predictions are shown on the chart on the right. 
 
 
 
‘In vitro’ Expression 
Expression of all the constructs was assessed by western blot. DNAs from wild-
type and deglycosylated constructs were transfected in parallel, cell supernatants and 
lysates were collected, and an SDS-PAGE and a western blot were run. All constructs 
expressed well (figure 13) and a band shift was observed when comparing each wild-type 
band with its deglycosylated counterpart (figures 13 and 14). 
Enzyme Used 
for Digestion
Bam HI Bam HI + Nhe I Sac I
6147 4746 3660
1401 1115
726
646
Expected Fragment Size(s)
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Figure 13: Western blot comparing the expression of wild-type and the deglycosylated 
constructs. The upper panels used a serum from animals immunized with a polyvalent 
vaccine combining all the wild-type DNA vaccine constructs. In the lower panels, the 
serum used was raised against a polyvalent vaccine combining all the deglycosylated 
DNA vaccine constructs. pSW3891 vector was used as a negative control. The arrows 
point at the position of gp120. 
 
 
As seen in figure 13, deglycosylated antigens were recognized by wild-type-
raised sera and vice-versa. Thus, the deglycosylated protein did not lose its conformation, 
since it can be recognized by a serum raised against wild-type gp120. Also, the band shift 
observed in more detail in figure 14, shows that the deglycosylations encoded in the 
vaccines actually occurred ‘in vitro’. 
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Figure 14: Western blot comparing the electrophoretic mobility of the wild-type and the 
deglycosylated gp120 clade G. The serum used was raised from rabbits immunized with 
wild-type gp120 clade G. pSW3891 vector was used as a negative control. The arrow 
shows the position of gp120. 
 
 Following acquisition of these data, the deglycosylated vaccine constructs cloning 
and characterization was concluded. Rabbit immunizations were also performed, and the 
sera were collected for further analysis, e.g. ELISA and neutralization assays, but these 
experiments will not be detailed in this thesis. 
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DISCUSSION 
 
 
Antigen Optimization:  
Effects of Codon Optimization, tPA Leader and Intron A 
 
Four steps must occur for gp120 protein secretion: first mRNA is synthesized 
from proviral DNA, then it is transported to the cytoplasm, and translation starts. The 
signal peptide targets the nascent protein to the endoplasmic reticulum, where synthesis is 
resumed. Finally, the protein goes through the Golgi to the extracellular space.  
 
The first step influenced by our modifications is the transport of mRNA to the 
cytoplasm. Both the codon-optimized and the non-optimized HXB2 constructs are Rev-
independent, since they lack the Rev response element (RRE). Rev is also responsible for 
stabilization of instability sequences (INS) present in HIV gag-pol mRNAs (Schwartz et 
al., 1992). Nevertheless, codon optimized constructs have a completely different 
nucleotide sequence, so no INS are present. This should result in cytoplasmic mRNA 
levels higher than those for the HXB2 mRNA. The mRNA levels have not been tested, 
but this assumption is made based on previous studies regarding the role of INS in gag-
pol mRNA levels (Schwartz et al., 1992; Schneider et al., 1997). However, the existence 
of instability sequences in the env mRNA has only been demonstrated in the region 
overlapping the Rev Responsive Element (RRE) (Brighty et al.¸1994). In our case, the 
RRE is not included in the cloned fragment of env, so if there was any effect of codon 
optimization on mRNA transport or instability it would be dependent on putative 
sequences homologous to the ones found in gag-pol, but whose presence has not yet been 
 59
proven. From the results, it is clear that the antibody response was always higher for the 
codon-optimized constructs (figure 5), which reflects higher ‘in vivo’ expression levels 
from the DNA vaccine. This might be due to the better tRNA availability, the putative 
positive effect of codon optimization on mRNA transport and stabilization, or both.  
 
The presence of intron A in the pre-mRNA also influences this nuclear export 
step. It is known that a spliceable transcript is more stable and yields higher cytoplasmic 
mRNA levels in mammalian expression systems (Luo et al., 1999). Transcription factor 
binding site homology sequences have been detected inside the sequence of intron A. 
This would have an effect in transcription form the CMV IE promoter. Several studies 
have been conducted to investigate the effects of introns in the expression levels obtained 
from plasmid vectors (Chapman et al., 1991; Cheng et al., 1993; Xu et al., 2001). Intron 
A is the largest of the four introns in the Cytomegalovirus immediate early gene. The 
promoter/enhancer region of this gene has proven one of the most powerful in 
mammalian expression vectors (Cheng et al., 1993).  Two mechanisms have been 
proposed as responsible for the increased expression levels provided by the presence of 
intron A: mRNA stabilization and transport to cytoplasm (Huang et al., 1990; Luo et al., 
1999), and binding of transcription factors (Chapman et al., 1991). In that study, a 
consensus-binding site for transcriptional activator NF1 was found in the intron A 
sequence. Mutations in that sequence triggered a decrease in the expression levels of 
reporter genes ‘in vitro’. Retardation gel experiments showed how the mutated sequences 
were less efficient in binding NF1, although this difference could not account for the 
expression differences observed when comparing constructs with or without intron A, 
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leaving other factors such as nuclear export as a possible explanation for this effect. The 
augmented expression observed in that study when intron A was included was not as 
evident when transcription occurred from SV40 early promoter instead of CMV IE 
promoter. Because of these reasons it is expected that those constructs carry intron A will 
show an increase in the expression levels. Data presented in this thesis did show an 
increase in ELISA signal for gp120 from mice sera when comparing codon optimized 
constructs with or without Intron A, although it was not a dramatic increase (see figure 
7). If we speculate with the possibility of the presence of instability sequences on env, 
intron A should not affect cytoplasmic mRNA levels of codon-optimized constructs as 
much as it does for the HXB2 (non-codon optimized) constructs. Since the cytoplasmic 
mRNA levels of the codon-optimized constructs are presumed to be already high due to 
the lack of instability sequences, an additional enhancement from intron A would not as 
conspicuous as it is for the HXB2 constructs. This effect is shown in figure 7: for the 
non-codon optimized constructs the antibody production was markedly different when 
comparing constructs with or without intron A, whereas the difference is very small when 
the codon-optimized constructs with and without intron A are compared.  
 
A codon bias closer to mammalian codon bias will expectedly enhance protein 
synthesis from viral mRNA. In our case, this would happen when the construct is codon 
optimized, as reflected by the higher specific antibody reactivity shown in figure 5. tRNA 
availability is more favorable to the constructs with a mammalian codon bias. From my 
results, this translation step cannot be discerned from the nuclear export, since mRNA 
was not measured. Nevertheless, the antibody production in constructs differing only in 
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codon optimization and without any of the other elements is markedly different, as seen 
in figure 8. 
 
Secretion is at the end of the protein synthesis pathway. The effect of enhanced 
secretion is appreciable only when the levels of intracellular protein are high, i.e. when 
the constructs carry either codon optimization or intron A, or both. The incorporation of a 
tPA leader should yield higher protein levels in the extracellular space. As seen in other 
studies (Chapman et al., 1991), the substitution of HIV leader sequence by the tPA leader 
sequence led to a substantial increase in expression levels of env protein. In the 
constructs featured in figure 9, protein synthesis was enhanced either by codon 
optimization or by the presence of intron A; therefore the effect of tPA leader inclusion is 
evident. 
 
 
 The mechanism underlying the inefficiency of HIV leader has been proposed (Li 
et al., 1994, 2000; Martoglio et al., 1997). According to these studies, the env signal 
sequence has particular characteristics distant from the expected for a typical signal 
sequence, which retards its own cleavage. The protein cannot start folding until cleavage 
of the signal sequence has occurred. The HIV signal sequence contains 5 positively 
charged amino acids in the N-terminal region, which is very uncommon for a signal 
sequence (see table VIII). It was observed that the presence of these residues did not 
influence the translocation into the endoplasmic reticulum (ER), but the cleavage of the 
signal sequence and therefore the protein folding (Li et al., 1994; Pancino et al., 1994). 
Experiments measuring gp140 and gp120 association with calnexin – an ER protein that 
 62
binds protein precursors while they still contain the signal sequence – showed a slow 
signal sequence cleavage kinetics. The correlation of this slow kinetics with folding was 
established by measuring disulfide bond formation and the precursor’s ability to interact 
with CD4. Uncleaved protein remains in the ER, leading to aggregation and misfolding. 
In figure 9, the lyates from the cells transfected with the constructs without tPA appeared 
as a smeared band spanning a long size range. This observation is consistent with the 
high likelihood of proteins with HIV leader to misfold or to aggregate. More sound proof 
of the HIV leader retarding protein folding and secretion was obtained by the 
construction of a chimeric VSV-G protein containing the HIV leader sequence (Li et al., 
2000). A putative immune system evasion role has been proposed for HIV signal 
sequence by which a retardation of the protein folding would lead to a decreased MHC-I 
antigen presentation (Srinivas et al., 1993; Martoglio et al., 1997). My antibody 
production results are definitely consistent with these previous studies, showing an effect 
on protein expression rate dependent on the leader sequence. Nevertheless, the high 
antibody levels observed from the animals immunized with the codon-optimized 
construct with the HIV leader sequence are more difficult to explain. It is possible that a 
better tRNA availability drove the protein synthesis forward once the leader sequence is 
already inside the endoplasmic reticulum, although whether this is enough to balance the 
impaired cleavage ability of HIV leader remains unknown.   
 
When comparing the reactivity of the antiserum from the mice immunized with 
HXB2 gp120 with tPA and without Intron A construct (gp120.HXB2 tPA+ Intron A-), 
against the codon-optimized (syn) antigen (see figure 5, lower left panel) and against the 
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HXB2 antigen (see figure 5 upper right panel), an interesting effect was seen: the 
heterologous reactivity was higher than the homologous reactivity. There is a possible 
explanation for this effect, and it is that the conformation of HXB2 gp120 ‘in vivo’ was 
slightly different than ‘in vitro’ whereas the conformation of the synthetic gp120 was 
closer ‘in vitro’ and ‘in vivo’. Assuming that both gp120s shared an epitope that was 
present ‘in vivo’, and that this epitope disappeared ‘in vitro’ only in the HXB2 gp120, 
antibodies would be raised against that particular epitope ‘in vivo’. When reactivity was 
tested against the HXB2 antigen produced ‘in vitro’, this epitope was not present and 
these antibodies were not reactive. When the heterologous reactivity was tested, the 
antigen was the synthetic gp120, which conserved the mentioned epitope ‘in vitro’, 
therefore the sera was reactive against this epitope and this accounted for the higher 
heterologous reactivity. 
 
 Unfortunately, the cell mediated immunity assays were not successful. The HXB2 
III B peptides had been used before and the results obtained here replicated the ones 
obtained before (personal communication from Dr. Wang). This peptide has been proven 
to be a T-cell epitope (Takeshita et al., 1995). Nevertheless, the B V3 peptides had not 
been tested before against a JR-FL construct (the codon optimized, syn constructs). It was 
assumed that they might react as well with JR-FL gp120, since both JR-FL and B gp120s 
are clade B. Without a positive reaction against the peptides that were supposed to be 
homologous for JR-FL, it is impossible to make a comparison between the different 
constructs, as it was done for the antibody response analysis. Therefore, the results from 
the cell-mediated immunity assays are inconclusive.  
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Epitope Exposure: 
Molecular Cloning and Characterization of Deglycosylated gp120 Vaccine 
Constructs 
 
This far, the deglycosylated constructs have been cloned and characterized, and 
the vaccinations have been performed. All the clones were expressed ‘in vitro’. From the 
western blot analysis, it can be concluded that the deglycosylated protein did not lose its 
conformation, since it can be recognized by a serum raised against wild-type gp120.  
Nevertheless, this is not enough evidence to prove the postulated epitope exposure upon 
deglycosylation. Future experiments could provide evidence supporting the postulated 
epitope exposure. This will require performing specific antibody reactivity assays and 
neutralization assays, which will not be covered in this thesis. The ELISAs have already 
been started, and the neutralization assays will be soon performed by Dr. Moubdjeka 
from the Nucleic Acid Vaccine Laboratory. 
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PERSPECTIVES 
 
 The present thesis has shown a series of attempts to improve gp120 
immunogenicity. Cloning and characterization of the optimized vaccine constructs has 
already been achieved. Also, preliminary evidence is supplied as to the expected efficacy 
of the modifications introduced. At this point more palpable proof needs to be provided, 
e.g. neutralization assay data. These experiments have all been conducted in mice and 
rabbits, it is necessary to advance in the evolutionary scale and reproduce them in 
primates before going into a clinical trial. Both the neutralization assays and the macaque 
studies will be very soon conducted by Dr. Lu’s laboratory and by our private partner 
Advance Bioscience Laboratories. 
 
 Another layer can be added to the modifications already depicted. Myself and 
other lab members are conducting experiments to generate a vaccine construct encoding 
gp120 plus the primary receptor CD4 and the co-receptor CCR5 or CXCR4. These 
proteins are going to be encoded in trans, separately or as fusion proteins comprising the 
extracellular domains of the co-receptor, CD4 and gp120. It has been previously shown 
how the interaction of gp120 with CD4 triggers the appearance of hidden epitopes (Thali 
et al., 1993; Carrillo and Ratner, 1996; Trkola et al., 1996); and how the formation of the 
tripartite protein complex leads to the exposure of the fusogenic domain of gp120. This 
raises the possibility to produce stable complexes ‘in vivo’ through DNA vaccination as a 
further attempt to raise neutralizing antibody.  
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 Once we have successfully tested the codon optimized construct, codon 
optimization is being expanded to every gp120 subspecies constructs. At this point, we 
have cloned and tested the ‘in vitro’ expression of several optimized gp120 constructs 
plus an optimized Gag construct. 
 
 As a refinement of the codon optimization experiment, a Fluorescence In Situ 
Hybridization (FISH) experiment is being conducting to compare the subcellular location 
of the vaccine RNAs generated by codon optimized constructs versus the non-optimized 
RNAs. It is expected to observe a difference in location and in nuclear transport 
efficiency. This experiment is being conducted in collaboration with Polly Xing, M.D., 
Ph.D. 
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